Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
Authors:
- 5 August 2019
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 38 (3) , 844-854
Abstract
Summary Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE). Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3–2.8 mg/kg) given every 3 weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Results Fifty-three patients received a median of 6 doses of DEDN6526A (range 1–49). The most common drug-related adverse events (>25% across dose levels) were fatigue, peripheral neuropathy, nausea, diarrhea, alopecia, and chills. Three patients in dose-escalation experienced a dose-limiting toxicity (infusion-related reaction, increased ALT/AST, and drug-induced liver injury). Based on cumulative safety data across all dose levels, the recommended Phase II dose (RP2D) for DEDN6526A was 2.4 mg/kg intravenous (IV) q3w. The pharmacokinetics of antibody-conjugated MMAE and total antibody were dose-proportional at doses ranging from 1.8–2.8 mg/kg. A trend toward faster clearance was observed at doses of 0.3–1.2 mg/kg. There were 6 partial responses (11%) in patients with metastatic cutaneous or mucosal melanoma, and 17 patients (32%) had prolonged stable disease ≥6 months. Responses were independent of BRAF mutation status but did correlate with ETBR expression. Conclusion DEDN6526A administered at the RP2D of 2.4 mg/kg q3w had an acceptable safety profile and showed evidence of anti-tumor activity in patients with cutaneous, mucosal, and uveal melanoma. ClinicalTrials.gov identifier: NCT01522664.Keywords
This publication has 23 references indexed in Scilit:
- An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of MelanomaClinical Cancer Research, 2011
- G protein-coupled receptors: novel targets for drug discovery in cancerNature Reviews Drug Discovery, 2010
- Roles of endothelin signaling in melanocyte development and melanomaPigment Cell & Melanoma Research, 2010
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateClinical Cancer Research, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- The endothelin axis: emerging role in cancerNature Reviews Cancer, 2003
- Expression of the endothelin-B receptor in pigment cell lesions of the skinVirchows Archiv, 2001
- Subtype-specific Trafficking of Endothelin ReceptorsJournal of Biological Chemistry, 2000